Physical Medicine Associates, LTD
Physical Medicine Associates, LTD was paid $1.79M by Medicaid between Jan 2018 and Dec 2024, across 31 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 75% of everything it billed.
MC LEAN, VA 22102
Next to other Interventional Pain Medicine Physician providers in Virginia
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,177 | $221K | |
| 2019 | 8,698 | $130K | |
| 2020 | 9,161 | $161K | |
| 2021 | 7,830 | $238K | |
| 2022 | 8,107 | $299K | |
| 2023 | 9,683 | $388K | |
| 2024incomplete | 7,811 | $349K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 75% | 34,753 | 30,095 | $1.34M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 16% | 13,646 | 10,881 | $283K |
| 64483 | 2.4% | 573 | 458 | $43K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.6% | 2,473 | 1,982 | $28K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | <1% | 233 | 185 | $15K |
| 77002 | <1% | 347 | 272 | $14K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 633 | 495 | $10K |
| 99215 | Doctor's office visit, returning patient (complex)Prolong outpt/office vis | <1% | 166 | 130 | $9K |
| 64493 | <1% | 97 | 71 | $8K | |
| 20610 | <1% | 184 | 136 | $5K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 649 | 533 | $3K |
| J3490 | Unclassified drugs | <1% | 1,409 | 1,084 | $3K |
19 more codes
| 99203 | Doctor's office visit, new patient (routine) | <1% | 51 | $2K |
| 64494 | <1% | 103 | $2K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 742 | $2K |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 12 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 194 | $2K |
| 20553 | <1% | 52 | $2K | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 950 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,551 | $1K |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 366 | $1K |
| 64495 | <1% | 57 | $885.60 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 2,498 | $803.88 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 88 | $717.66 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 22 | $597.69 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 96 | $429.49 |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 64 | $88.99 |
| 99406 | <1% | 104 | $49.74 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 281 | $26.63 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 35 | $24.77 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 38 | $0.02 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
Who's on the registration
| Provider | Location | Paid |
|---|---|---|
| Center for Pain Management, LLC | Hagerstown, MD | $18.80M |
| Interventional Pain Center PLLC | Fayetteville, NC | $6.14M |
| Asc Development Company, LLC | Hagerstown, MD | $113K |
| Asc Development Company, LLC | Frederick, MD | $42K |
| Asc Development Company, LLC | Germantown, MD | $31K |
| Florida Pain and Rehabilitation Associates INC | Delray Beach, FL | $25K |
| Asc Development Company, LLC | Pikesville, MD | $24K |
| Asc Development Company, LLC | Glen Burnie, MD | $24K |
| Center for Pain Management, LLC | Columbia, MD | $15K |
| Asc Development Company LLC | White Plains, MD | $14K |
| Asc Development Company, LLC | Bel Air, MD | $7K |
| NSPC Surgery Center of Maryland LLC | Oxon Hill, MD | $6K |
| National Surgical Centers of America LLC | Winter Park, FL | $2K |
| Florida Pain and Rehabilitation Associates INC | Delray Beach, FL | $377.09 |
| Physical Medicine Associates LTD | Oxon Hill, MD | $0.00 |
| Pain Consultants Asc LLC | Pascagoula, MS | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.